Trending...
- Red Light Therapy: A Breakthrough Treatment for Aging Eyesight
- The Millennium Alliance Is Recognized As A Top Workplace In New York City
- Celebrate Black Music Month — An Unforgettable Evening with Morace Landy: Music Industry Legend & CEO, Evolution3, June 6, 6-8:30 PM, Harlem, NY
NEW YORK--(BUSINESS WIRE)--Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Sarepta Therapeutics, Inc. ("Sarepta" or the "Company") (NASDAQ: SRPT) on behalf of Sarepta stockholders. Our investigation concerns whether Sarepta has violated the federal securities laws and/or engaged in other unlawful business practices.
Click here to participate in the action.
On March 16, 2023, Sarepta issued a press release announcing that "at its late cycle meeting for the SRP-9001 (delandistrogene moxeparvovec) biologics license application (BLA), the U.S. Food and Drug Administration's Office of Therapeutics (OTP) has determined that an advisory committee meeting will be held for SRP-9001 in advance of the May 29, 2023 regulatory action date." Sarepta's Chief Executive Officer stated in the press release that "[w]hile we are disappointed that we must communicate a change in decision after our prior statement on the topic, we are not disappointed with the decision to hold an advisory committee. We had been preparing for an advisory committee meeting from the filing of the BLA in the fall of 2022."
More on Nyenta.com
On this news, Sarepta's stock price fell $26.98 per share, or 18.03%, to close at $122.69 per share on March 17, 2023.
If you purchased or otherwise acquired Sarepta shares and suffered a loss, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Marion Passmore by email at investigations@bespc.com, by telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you.
About Bragar Eagel & Squire, P.C.:
Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York and California. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes.
More on Nyenta.com
Contacts
Bragar Eagel & Squire, P.C.
Brandon Walker, Esq.
Marion Passmore, Esq.
(212) 355-4648
investigations@bespc.com
www.bespc.com
Click here to participate in the action.
On March 16, 2023, Sarepta issued a press release announcing that "at its late cycle meeting for the SRP-9001 (delandistrogene moxeparvovec) biologics license application (BLA), the U.S. Food and Drug Administration's Office of Therapeutics (OTP) has determined that an advisory committee meeting will be held for SRP-9001 in advance of the May 29, 2023 regulatory action date." Sarepta's Chief Executive Officer stated in the press release that "[w]hile we are disappointed that we must communicate a change in decision after our prior statement on the topic, we are not disappointed with the decision to hold an advisory committee. We had been preparing for an advisory committee meeting from the filing of the BLA in the fall of 2022."
More on Nyenta.com
- Kessler Topaz Meltzer & Check, LLP Reminds Icahn Enterprises L.P. (IEP) Investors of July 10, 2023 Lead Plaintiff Deadline and Urges Investors with Substantial Losses to Contact the Firm
- How to Navigate Hormonal Mayhem: A Groundbreaking Book on Perimenopause, Endometriosis, and Beyond
- Rochester: Mayor Evans Encourages Residents to Heed Monroe County Department of Health Advisories
- Get Ready for Fireworks in Sexy Red, White, and Blue Bustier Babydoll Lingerie
- THE SALMON FACTOR WINS GOLD EFFIE AWARD IN THE UNITED STATES USA - English España - español
On this news, Sarepta's stock price fell $26.98 per share, or 18.03%, to close at $122.69 per share on March 17, 2023.
If you purchased or otherwise acquired Sarepta shares and suffered a loss, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Marion Passmore by email at investigations@bespc.com, by telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you.
About Bragar Eagel & Squire, P.C.:
Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York and California. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes.
More on Nyenta.com
- Financial IT Launches Fintech Pathfinder: Showcasing the Most Promising Fintech Startups
- Return of Professional Basketball to Quebec City
- Leading Independent Proxy Advisory Firms ISS and Glass Lewis Support WisdomTree's New Director Nominee Shamla Naidoo and Recommend Against ETFS Capital Chairman Graham Tuckwell
- Wágner Resurfaces with Second Single "I Ran" After 30-Year Hiatus
- SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Tingo Group, Inc. - TIO
Contacts
Bragar Eagel & Squire, P.C.
Brandon Walker, Esq.
Marion Passmore, Esq.
(212) 355-4648
investigations@bespc.com
www.bespc.com
Filed Under: Business
0 Comments
Latest on Nyenta.com
- KYC2020 Offers Free Sanctions Screening for Non-Commercial Use
- Introducing RecipeNFT: The Revolutionary Platform for Preserving Family Recipes on the Avalanche Blockchain
- Introducing Obitz.io: Revolutionizing Obituaries with Blockchain Technology
- Bronx Chiropractor, Dr. Ralph Napolitano, Expands Practice to Serve Bronx and Brooklyn
- New Epic Fantasy - Shadow of the Soul Blade By Jay Roland
- Wallaroo.AI Launches Unique Workload Orchestration Capabilities to Help Scale Production Machine Learning (ML) Workflows 5- 10x, with 40% Time Savings
- BURFORD CAPITAL TO HOST GLOBAL RETAIL SHAREHOLDER CALL ON JUNE 21, 2023
- Bent Danholm of MAXIM Realty Orlando Joins Forces With Tech Company to Improve Target Marketing of Homes in Central Florida
- VenturSeed Machine-Learning/Artificial Intelligence Labs Launches for Students and Promising Pre-Pre Seed Startups
- ERC Deadline (June 2023): Employee Retention Credit Deadline Guidance Shared by Better Business Advice
- Rochester: J.U.S.T. L.A.W. Initiative Student Essay Winners to be Recognized at Awards Ceremony
- Bit Digital, Inc. Announces Monthly Production Update for May 2023
- SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NextEra Energy, Inc. - NEE
- Stapleton Group and Sorokin & Associates Announce Strategic Partnership
- Politan Comments on Masimo's Recent Board Announcement
- Blue Collar Barons Launches as the First Construction-themed NFT Web3 Game
- Ashtyn Montgomery and Cruz Textures Partner with Doe Sports
- JustFoodForDogs In-Store Kitchen Now Open at Petco's Union Square Location
- Loretta Ana Kaufman to Exhibit in The National Association of Women Artists 134th Annual Exhibition
- KBRA Assigns Preliminary Ratings to GLS Auto Select Receivables Trust 2023-1